Inspection prep notes · Sterility and contamination control
Cleanrooms: pressure differentials, HEPA and airflow
Also called: cleanroom, clean room, pressure differential, HEPA, smoke study
FDA looks less at whether a cleanroom is installed than at whether its pressure differentials and airflow are confirmed and maintained under actual working conditions. The findings below are quoted from warning letters and FDA 483s.
What inspectors cited
1Smoke studies were not adequately performed under dynamic conditions
Smoke studies conducted at your facility did not include a dynamic evaluation of LAFW or (b)(4) operations and therefore do not adequately demonstrate that unidirectional airflow effectively controls air quality during aseptic manufacturing.
FDA Warning Letter · Northland Nuclear Medicine, LLC · 2026-10-27
Smoke studies were inadequately performed under dynamic conditions.
FDA 483 · Strive Pharmacy LLC · 2026-11-13 · View document
2Adequate pressure differentials between areas were not maintained
Furthermore, you failed to maintain an adequate differential pressure between the ISO 5 area and the warehouse, and did not continuously monitor that pressure.
FDA Warning Letter · BRS Analytical Services, LLC · 2025-10-21 · View document
Our inspection found the pressure differentials in the aseptic manufacturing rooms were inadequate. For example, the aseptic filling rooms had lower pressure than the adjacent rooms.
FDA Warning Letter · Pharmathen International S.A. · 2026-06-16 · View document
3Gaps around HEPA filters were not properly closed
Your cleanrooms (e.g., ISO 5 filling line and ISO 7 weigh and formulation rooms) were inadequately designed and maintained to facilitate adequate cleaning and proper operations. For example, excessive caulking and tape were used to repair gaps around ceiling HEPA filters, air vents, and (b)(4) .
FDA Warning Letter · Liebel-Flarsheim Company LLC · 2025-11-04
Visible gaps between the [redacted] used to cover HEPA filters.
FDA 483 · Eugia Steriles Private Limited · 2026-10-26 · View document
4ISO 5 areas and hoods were not routinely certified
Your facility lacked routine and rigorous certification of the ISO 5 areas, including airflow visualization studies performed under dynamic conditions.
FDA Warning Letter · SCA Pharmaceuticals, LLC · 2026-10-13 · View document
Further, the laminar airflow hood used during repackaging has not been qualified, certified, or routinely maintained.
FDA 483 · PReye LLC · 2026-10-23 · View document
5Airflow in the filling area was not shown to be free of turbulence
Significant turbulence was observed in your vial filling line airflow visualization videos. However, your firm concluded that airflow was adequate.
FDA Warning Letter · USV Private Limited · 2026-11-10
The static study performed shows air turbulence in the Grade A filling area of filling machine [redacted] at the level of the HEPA filter where the ceiling meets the surrounding [redacted] barrier.
FDA 483 · Apotek Production & Laboratorier AB · 2026-10-22 · View document
Questions to check against your procedures
- Do smoke studies include a dynamic evaluation that reflects actual operations?
- Is the pressure differential between the ISO 5 area and adjacent areas maintained and continuously monitored?
- Is the aseptic filling room kept at a higher pressure than the adjacent rooms?
- Are ceiling HEPA filters and air vents free of gaps and of caulk or tape repairs?
- Are ISO 5 areas and laminar airflow hoods qualified and certified routinely?
- Is there any study that judged airflow adequate although turbulence was visible in the airflow visualization videos?
Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.